| 1. |
張鑫, 郭志華, 李京沛, 等. 呼吸系統炎癥性肌纖維母細胞瘤的診斷與治療. 中國現代藥物應用, 2017, 11(19): 37-39.
|
| 2. |
郭峰, 張志庸, 崔玉尚, 等. 胸部炎性肌纖維母細胞瘤的外科治療. 中國胸心血管外科臨床雜志, 2010, 17(3): 202-205.
|
| 3. |
Gupta S, Goyal P, Yang Y, et al. Tracheal inflammatory myofibroblastoma: A rare tumor of the trachea. Cureus, 2019, 11(4): e4484.
|
| 4. |
杜江, 張林. 胸部炎性肌纖維母細胞瘤的臨床特點及診治分析. 中國醫科大學學報, 2014, 43(6): 570-573.
|
| 5. |
薛正和, 潘利周, 劉穩芳. 肺外炎性肌纖維母細胞瘤的影像學表現. 醫學影像學雜志, 2020, 30(1): 65-68.
|
| 6. |
劉偉南, 劉晉波, 賀中杰, 等. 縱隔炎性肌纖維母細胞瘤的螺旋CT表現(附7例分析). 中國CT和MRI雜志, 2015, 13(5): 52-55.
|
| 7. |
Kakitsubata Y, Theodorou SJ, Theodorou DJ, et al. Myofibroblastic inflammatory tumor of the lung: CT findings with pathologic correlation. Comput Med Imaging Graph, 2007, 31(8): 607-613.
|
| 8. |
Dong A, Wang Y, Dong H, et al. Inflammatory myofibroblastic tumor: FDG PET/CT findings with pathologic correlation. Clin Nucl Med, 2014, 39(2): 113-121.
|
| 9. |
劉海玲, 劉斌, 陶景山, 等. 胸部炎性肌纖維母細胞瘤的影像征象分析. 世界最新醫學信息文摘, 2019, 19(68): 194, 201.
|
| 10. |
張微竹, 付莉, 鄧力. CT結合MRI檢查對小兒炎性肌纖維母細胞瘤的診斷效果分析. 中國CT和MRI雜志, 2020, 18(8): 150-152.
|
| 11. |
張競, 王云喜, 初向陽, 等. 胸部炎性肌纖維母細胞瘤的診斷和治療. 南方醫科大學學報, 2012, 32(1): 135-138.
|
| 12. |
廖江, 陳加優, 鄭祥, 等. 炎性肌纖維母細胞瘤的影像學表現與病理對照研究. 中國醫藥導報, 2018, 15(31): 138-141, 154.
|
| 13. |
Li F, Guo H, Qiu H, et al. Ureteral inflammatory myofibroblastic tumor: A case report and literature review. Medicine (Baltimore), 2018, 97(46): e13177.
|
| 14. |
Tothova Z, Wagner AJ. Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors. Curr Opin Oncol, 2012, 24(4): 409-413.
|
| 15. |
金琳羚, 朱巖, 金宇, 等. 胸部炎性肌纖維母細胞瘤臨床特征及診療分析. 中國呼吸與危重監護雜志, 2020, 19(6): 563-567.
|
| 16. |
Nagumo Y, Maejima A, Toyoshima Y, et al. Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report. Int J Surg Case Rep, 2018, 48: 1-4.
|
| 17. |
Mossé YP, Voss SD, Lim MS, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: A children's oncology group study. J Clin Oncol, 2017, 35(28): 3215-3221.
|